Ophthalmology

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VEGF chemical to halt the development of extra blood vessels over macula that deteriorate the vision, which is one of the biggest Wet Age-related macular degeneration treatment market barriers.  However, with the rise in geriatric population, and advancement in R&D, the number of companies fueling the wet-age related treatment market has increased ...